02:42 , Mar 2, 2016 |  BC Extra  |  Financial News

Savara tops off $20M series C round

Savara Pharmaceuticals (Austin, Texas) raised $10 million in the second close of a series C round, bringing the round's total to $20 million. President and CEO Robert Neville told BioCentury the funds came from boutique...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Clinical News

AeroVanc: Phase II data

A double-blind, U.S. Phase II trial in 87 CF patients with persistent MRSA lung infection showed that twice-daily inhaled AeroVanc met the primary endpoint of reducing MRSA density in sputum from baseline at day 29...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Clinical News

AeroVanc: Completed Phase II enrollment

Savara completed enrollment of 80 patients with CF in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 32 and 64 mg inhaled AeroVanc twice daily for 28 days. AeroVanc has Qualified Infectious Disease Product (QIDP),...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Clinical News

AeroVanc regulatory update

Savara said FDA granted Qualified Infectious Disease Product (QIDP) designation for AeroVanc to treat persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis (CF) patients. The compound is now eligible for an additional 5...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Company News

Savara, Cystic Fibrosis Foundation infectious, drug delivery news

Savara received a $1.7 million research award from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the drug development affiliate of the not-for-profit foundation, to develop AeroVanc . The product is in a Phase II trial to...
07:00 , Apr 29, 2013 |  BC Week In Review  |  Clinical News

AeroVanc: Phase II started

Savara began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily 32 and 64 mg AeroVanc for 28 days in about 80 patients. Patients with co-infected with Pseudomonas aeruginosa will undergo a 28-day run-in,...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Clinical News

AeroVanc regulatory update

Savara said FDA granted Orphan Drug designation for AeroVanc to treat methicillin-resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis (CF) patients. The inhaled dry powder formulation of vancomycin in a capsule-based inhaler has completed Phase...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Clinical News

AeroVanc: Phase Ib data

Top-line data from 6 non-MRSA infected CF patients in the Phase Ib portion of an open-label, Australian Phase Ia/Ib trial showed that single doses of 32 and 80 mg AeroVanc were well tolerated. Savara said...
07:00 , May 14, 2012 |  BC Week In Review  |  Clinical News

AeroVanc: Phase Ia data

Top-line data from 18 healthy volunteers in the Phase Ia portion of an open-label, vancomycin-controlled, Australian Phase Ia/Ib trial showed that single doses of 16, 32 and 80 mg AeroVanc were well tolerated with only...